Tezepelumab-ekko is a biologic injected subcutaneously every four weeks as an ad on maintenance therapy for patients age 12 years or older with severe asthma.
Tezepelumab is a human monoclonal antibody used for the treatment of asthma.
It is sold under the brand name Tezspire.
Routes of administration subcutaneous.
It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
It competes against a critical part of the TSLPR binding site on TSLP.
It is indicated for the add-on maintenance treatment of people aged twelve years and older with severe asthma.
Side effects include arthralgia and pharyngitis.
It is effective in reducing the number of severe asthma flare‑ups.
It is effective in preventing serious conditions or enhancing patient adherence.
It is used for treatment of severe asthma without limitation to a specific type of asthma.
Significantly reduced the annualized rate of asthma attacks compared with placebo.
Tezepelumab therapy leads to significantly greater reductions in the size of nasal polyps, severity of nasal congestion, reduction in sinonasal symptoms, and the use of nasal polyp surgery and systemicmsteroids than placebo in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps (WAYPOINT study investigators).